Replies to post #234845 on Biotech Values

[DewDiligence]

ENLV—(-54%)—reports purportedly-positive phase-2 data in sepsis:

https://finance.yahoo.com/news/enlivex-announces-topline-results-phase-120500002.html

Enlivex Therapeutics Ltd., a clinical-stage macrophage reprogramming immunotherapy company, today announced positive indication of effect and safety results from its Phase II study of Allocetra in patients with sepsis, in which 120 patients enrolled.

LOL re the use of the phrase, “positive indication of effect.”